Be the first to like this
Technavio’s market research analyst predicts the global postmenopausal osteoporosis drugs market to grow steadily at a CAGR of more than 4% over the forecast period. With the expected launch of promising pipeline molecules, the market for postmenopausal osteoporosis has a positive outlook in the coming years. The postmenopausal osteoporosis drugs market is characterized by the presence of promising late-stage molecules that are being developed by the major and upcoming players in this market. Some of the late-stage pipeline molecules that are envisaged to be launched during the forecast period are Tarsa Therapeutics’ TBRIA, romosozumab, Merck’ odanacatib (Phase III), and Radius Health’s abaloparatide (Phase III).